Press release
Accession Therapeutics doses first patient in new cancer immunotherapy trial
November 26, 2025Research and Development Accession Therapeutics, Oncology
Biopharmaceutical company Accession Therapeutics has announced the dosing of the first patient in the phase 1 clinical trial of TROCEPT-01 …
Lubrizol announces an important milestone for its novelpatented excipient, Apisolex™ polymer
June 10, 2025Research and Development Apisolex polymer, Good Manufacturing Practices (GMP) guidelines, Lubrizol, Pharmacy, clinical trial
June 10, 2025 – Lubrizol announces that an Apisolex™ polymer excipient-enabled drugformulation is in Phase 1 clinical trials. Introduced to …
New CAR T Vision Coalition and roadmap report to launch at ASCO aims to double patients treated with CAR T-cell therapy by 2030
June 3, 2025Research and Development American Society of Clinical Oncology, CAR T Vision, CAR T-cell therapy, International Myeloma Foundation, Kite, Leukemia & Lymphoma Society, Oncology, blood cancer
For people living with aggressive blood cancers, CAR T-cell therapy offers hope for a longer, healthier life, and for some, …
NICE recommends mirikizumab (Omvoh ▼) for previously treated moderately to severely active Crohn’s disease 1
May 30, 2025Research and Development Crohn’s disease, Eli Lilly and Company, Gastrointestinal tract, Medicines and Healthcare products Regulatory Agency (MHRA)(, NHS England and Wales, National Institute for Health and Care Excellence (NICE), Omvoh, inflammatory bowel disease (IBD), mirikizumab
In the Phase 3 VIVID-1 trial, patients treated with mirikizumab experienced significant improvement in clinical remission and endoscopic response at …
UK Researcher Wins Prestigious IBSA Foundation Fellowship for Pioneering Dermatology Study
May 28, 2025Medical Communications, Research and Development Dermatology, IBSA Foundation Fellowship, Institut Biochimique SA (IBSA), Masami Ando Kuri, Milan Italy, Wellcome Sanger Institute, dermatology
Masami Ando Kuri from the Wellcome Sanger Institute named one of six global winners of the 2024 IBSA Foundation Fellowships. …
PL BioScience and DewCell sign LOI to Jointly Develop Artificial Human Platelets for Scalable, Animal-Free Cell Culture Media
May 23, 2025Research and Development Animal-Free, Artificial Human Platelets, Corporate, DewCell, Haematology, Human Platelet Lysate, Letter of Intent, Oncology, PL Bioscience
PL BioScience and DewCell Biotherapeutics have signed a Letter of Intent (LOI) for the development and supply of artificial human …
Another Day Pharma announces successful Phase II trial results for BZ371A in post-prostatectomy erectile dysfunction
May 22, 2025Research and Development Another Day Pharma, Genito-Urinary system, clinical trial, erectile dysfunction, prostate cancer, prostatectomy
First-in-class therapeutic peptide BZ371A confirmed as effective and well-tolerated 20 May 2025. Another Day Pharma Ltd, a company developing innovative …
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
May 22, 2025Market Access, Research and Development Haematology, Hympavzi, NHS, NICE, Pfizer, haemophilia B, marstacimab
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care Excellence (NICE) has published final …
Takeda announces launch of Framework to help support patient access to life-extending combination treatments
February 25, 2025Business Services Cancer, HIV/AIDS, Immunology, NHS, NICE, Oncology, Takeda, VPAG, patient access
The Conceptual Implementation Framework outlines critical points within the UK healthcare access ecosystem to help improve the introduction of combination …
Cardinal Health’s Kangaroo OMNI™ Enteral Feeding Pump to launch in new international markets in 2025
February 6, 2025Sales and Marketing Kangaroo, enteral, feeding pump
The next generation Kangaroo OMNI™ enteral feeding pump delivers nutrition and hydration from hospital to home. DUBLIN, Ireland, Feb.4, 2025 …
Bayer UK Launches New CanesMeno® Educational Hub and Product Range to Transform Menopause Support
January 30, 2025Medical Communications
29 January 2025 – Reading, UK – Bayer Consumer Health is entering the menopause category for the first time in …
Pharmapack Award Winners 2025 redefining pharmaceutical packaging and drug delivery
January 23, 2025Paris, Pharmapack 2025, Winners, pharmaceutical packaging and drug delivery
Award winners by category DELIVERY AND DEVICE INNOVATION SHL Medical for Elexy™ reusable electromechanical autoinjector ECO-DESIGN WINNER Huhtamaki for Omnilock™ …
Pharmapack Europe the ‘Heart of Pharma’ Start-ups in Paris
January 23, 2025Medical Communications, Public Relations Heart of Pharma, Paris, pharmapack
Six start-ups bestowed with new ‘heart of pharma’ commendation in recognition of innovations advancing drug delivery and packaging 22 January …
First patients treated with HEMGENIX® (etranacogene dezaparvovec) gene therapy for haemophilia B in Denmark
January 21, 2025Sales and Marketing CSL, Denmark, genetic, haemophilia, treatment
21 January 2025 – Copenhagen, Denmark – CSL Behring Denmark today announced that the first Danish patients with haemophilia B …
Pharmapack Predictions 2025: the Good the Bad and…. the Donald 2.0
January 17, 2025CPhI, Pharmpack, biologics, predictions
Biologic approvals, drug delivery advancements, GLP-1 generics and the long-sought funding return to drive a record year in 2025 13 …
Latest content
